Recent News

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma (PENINSULA)

March 22, 2024

In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma.

3D Printing and Optical Scanning Can Improve Mesothelioma Treatment

March 22, 2024

New treatments and technologies offer hope for mesothelioma patients. One technology, 3D printing and optical scanning, has the potential to help those suffering with mesothelioma. The technologies refine and enhance…

Exercise to Boost Immunity in Advanced Cancer (BICEP)

March 15, 2024

The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expression

An Iowa School was Fined for Exposing Workers to Asbestos

March 15, 2024

An Iowa school district could be fined thousands of dollars for having employees work inside an asbestos-contaminated building. State records were recently released showing that the Iowa Occupational Safety and…

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

March 8, 2024

This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.

Imerys Talc America and Cyprus Mines Corporation are Creating a Trust for Asbestos Victims

March 8, 2024

Imerys Talc America and its former owner, Cyprus Mines Corporation, will create a collective $862 million trust. The reason for the trust is to settle personal injury claims that allege…

Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration (PITHAC)

March 1, 2024

Within the context of pleural carcinosis, the present study is a dose escalation with determination of the maximum tolerated doses (MTD) of pressurized cisplatin administration associated to moderate hyperthermia in the pleura. This will be followed by an expansion phase at the recommended dose (RD).

ADI-PEG20 Improves Survival in Mesothelioma Patients

March 1, 2024

ADI-PEG20 is showing promising results for mesothelioma. It is the first treatment to be fully incorporated with chemotherapy in 20 years. The drug will bring hope to thousands of mesothelioma…

Asbestos and Other Carcinogens Were in U.S. Missile Silos

February 23, 2024

The U.S. Air Force is investigating asbestos and other carcinogens at nuclear missile bases. According to the Associated Press, the use of these carcinogens dates back to the 1980s. There…

Galinpepimut-S Alongside Opdivo Improves Survival in Mesothelioma Patients

February 16, 2024

Sellas Life Sciences recently reported results from its Phase I clinical trial showing that survival was improved in pleural mesothelioma patients due to its treatment. The trial looked at the…